Arrowhead Pharmaceuticals(FRA) HDP1

Market Cap€10.02B

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€71.20

+0.37%

+0.26Today

Arrowhead Pharmaceuticals Financials at a Glance

Market Cap

€10.02B

Revenue (TTM)

€574.06

Net Income (TTM)

-€233.41

EPS (TTM)

-€1.92

P/E Ratio

-36.88

Dividend

€0.00

Beta (Volatility)

0.13 (Low)

Dividend

€0.00

Beta (Volatility)

0.13 (Low)

Price

€71.20

Volume

Open

€70.54

Price

€71.20

Volume

Open

€70.54

Previous Close

€71.20

Daily Range

€69.54 - €71.50

52-Week Range

€18.82 - €80.72

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

0.13 (Low)

Price

€71.20

Volume

Open

€70.54

Previous Close

€71.20

Daily Range

€69.54 - €71.50

52-Week Range

€18.82 - €80.72

Estimated Earnings Date

N/A

HDP1 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Industry

Biotechnology

Sector

Health Care

Employees

711

CEO

Christopher Richard Anzalone, PhD

Website

www.arrowheadpharma.com

HDP1 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-64.40%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-2.71%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€10.02B

Shares Outstanding

141.25M

Volume

Avg. Volume

12.621

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Arrowhead Pharmaceuticals Performance Analysis

Arrowhead Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-09-30	EUR 224,918,344	94.3%
2023	2023-09-30	EUR 225,856,146	0.4%
2024	2024-09-30	EUR 3,275,943	-98.5%
2025	2025-09-30	EUR 751,284,990	22833.4%

Arrowhead Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-09-30	EUR -1.54	35.9%
2023	2023-09-30	EUR -1.80	16.8%
2024	2024-09-30	EUR -4.62	155.9%
2025	2025-09-30	EUR -0.01	-99.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€64.72

+2.6%

Gross Profit

€58.99

+3.1%

Gross Margin

91.15%

+1.2%

Market Cap

€10.02B

N/A

Market Cap/Employee

€14.25

N/A

Employees

711

N/A

Net Income

-€153.88

+1.0%

EBITDA

-€140.56

+1.0%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€1.25K

+74.3%

Total Debt

€1.20K

+2.0%

Accounts Receivable

€16.43

+2.0%

Inventory

€0.00

N/A

Long Term Debt

€1.16K

+2.1%

Short Term Debt

€39.64

+1.0%

Return on Assets

-18.15%

+1.5%

Return on Invested Capital

-31.34%

+0.9%

Free Cash Flow

-€155.45

+1.0%

Operating Cash Flow

-€152.11

+1.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,634.27-0.01%

^DJIDJI

^DJIDJI$52,797.46-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,099.39-0.01%

BTCBitcoin

BTCBitcoin$77,103.00-0.02%

SPCXSPCX

SPCXSPCX$143.28-0.00%

AAPLAAPL

AAPLAAPL$324.80+0.03%

AMZNAMZN

AMZNAMZN$255.17-0.02%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$14.06+0.06%

NVDANvidia

NVDANvidia$217.44-0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.33-0.06%

INTCIntel

INTCIntel$88.97-0.01%

ONDSOndas

ONDSOndas$7.04-0.08%

NUNu Holdings

NUNu Holdings$14.46-0.01%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.38-0.02%

Questions About HDP1

What is the current price of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals is trading at €71.20 per share.

What is the 52-week range for Arrowhead Pharmaceuticals?

Over the past 52 weeks, Arrowhead Pharmaceuticals has traded between €18.82 and €80.72.

How much debt does Arrowhead Pharmaceuticals have?

As of the most recent reporting period, Arrowhead Pharmaceuticals reported total debt of €1.20B.

How much cash does Arrowhead Pharmaceuticals have on hand?

Arrowhead Pharmaceuticals reported €47.90M in cash and cash equivalents in its most recent financial results.

What is Arrowhead Pharmaceuticals’s dividend yield?

Arrowhead Pharmaceuticals does not currently have a dividend yield.

Arrowhead Pharmaceuticals(FRA) HDP1

Arrowhead Pharmaceuticals Financials at a Glance

HDP1 News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Arrowhead Pharmaceuticals

HDP1 Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Arrowhead Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About HDP1

What is the current price of Arrowhead Pharmaceuticals?

What is the 52-week range for Arrowhead Pharmaceuticals?

How much debt does Arrowhead Pharmaceuticals have?

How much cash does Arrowhead Pharmaceuticals have on hand?

What is Arrowhead Pharmaceuticals’s dividend yield?

Premium Investing Services